ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
NCT05746559
Recruiting
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
04/14/2025
Locations: Research Site, Tucson, Arizona +209 locations
Conditions: Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
Register for Updates
Michigan Youth Violence Prevention Center: Building Evidence for Gun Violence Prevention - SafERteens Implementation
NCT05821205
Recruiting
The purpose of this study is to determine the preliminary efficacy (via a micro-randomized trial \[MRT\] design) of augmenting Enhanced-Replicating Effective Program (E-REP) with engagement strategies to increase and sustain reach by healthcare providers (e.g., nurses, social workers) during implementation of the SafERteens program across multiple healthcare settings.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: University of Michigan, Ann Arbor, Michigan +7 locations
Conditions: Violence in Adolescence
Register for Updates
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
NCT05976165
Recruiting
Researchers hope to determine how often small intestinal bacterial overgrowth occurs after taking proton pump inhibitors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Gastroesophageal Reflux, Regurgitation, Heartburn
Register for Updates
Improving the Mental Health of Home Health Aides
NCT06071221
Recruiting
The goal of this study is to improve the mental health of home health aides, a workforce that provides care for adults at home but whose own health has been historically poor. The main questions the study aims to answer are: * Will a health program called Living Healthy, which provides health education and support with positive thinking, be used by home health aides and do they like it? * Does Living Healthy actually improve home health aides' mood compared to what they usually do to take care... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: 1199 SEIU Home Care Industry Education Fund, New York, New York +1 locations
Conditions: Mental Health Issue
Register for Updates
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
NCT06158854
Recruiting
Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by clonal bone marrow plasma cells. This is a study to determine adverse events and change in disease activity in adult participants with AL amyloidosis treated with ABBV-383. Etentamig (ABBV-383) is an investigational drug being developed for the treatment of AL amyloidosis. This study in broken into... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Sylvester Comprehensive Cancer Center - University of Miami /ID# 255856, Miami, Florida +18 locations
Conditions: Immunoglobulin Light Chain (AL) Amyloidosis
Register for Updates
Menthol, Inflammation, and Nicotine Transition Study
NCT06232447
Recruiting
This study will focus on examining the potential impact of menthol flavoring in cigarettes on biomarkers of systemic inflammation as a subclinical indicator of cardiovascular disease risk.
Gender:
ALL
Ages:
Between 21 years and 85 years
Trial Updated:
04/14/2025
Locations: Rosalind Franklin University of Medicine and Science, North Chicago, Illinois
Conditions: Cigarette Smoking, Inflammatory Response
Register for Updates
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
NCT06298734
Recruiting
The purpose of this study is to determine whether high-intensity exercise and high-fiber diet are feasible and improve various health outcomes among participants with advanced melanoma receiving immunotherapy. The names of the groups in this research study are: * High-Intensity Exercise (EX) * High-fiber Diet (DT) * Combined High-Intensity Exercise and High-Fiber Diet (COMB) * Attention Control (AC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Melanoma (Skin), Skin Cancer, Advanced Melanoma
Register for Updates
A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)
NCT06333678
Recruiting
In this study, the researchers will look at whether having participants switch from durvalumab to sotorasib when they have detectable minimal residual disease (MRD) is an effective treatment approach for locally advanced non-small cell lung cancer (LA-NSCLC). The researchers will see whether this switch to sotorasib can control LANSCLC longer compared to the treatment approach of staying on durvalumab (and not switching to sotorasib).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: University of Miami (Data Collection Only), Miami, Florida +10 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
NCT06412666
Recruiting
The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
04/14/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +26 locations
Conditions: Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Register for Updates
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
NCT06495125
Recruiting
This phase II trial tests how well defactinib and avutometinib in combination with nivolumab works in treating patients with LKB1-mutant non-small cell lung cancer that has not responded (refractory) to an anti-PD1 treatment and may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Defactinib and avutometinib belong to a class of drugs called kinase inhibitors. These drugs target kinase proteins found in tumor cells. Tumor cells need... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Emory University Hospital Midtown, Atlanta, Georgia +2 locations
Conditions: Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Register for Updates
Effect of Statins on Crohn's Disease
NCT06538649
Recruiting
The goal of this clinical trial is to learn if statins work to prevent strictures in adults with Crohn's disease. The main question it aims to answer is: * Can statins reduce the formation of strictures in participants with stricturing Crohn's disease? Researchers will compare statins to a placebo (a look-a-like substance that contains no drug) to see if statins work to prevent strictures from forming. Participants will: * Take statins or a placebo every day for 6-12 months * Visit the clinic... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/14/2025
Locations: Stanford University, Stanford, California
Conditions: Crohn's Ileocolitis, Crohn Disease
Register for Updates
A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
NCT06628362
Recruiting
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/14/2025
Locations: Pinnacle Research Group, Llc; Central, Anniston, Alabama +42 locations
Conditions: Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Register for Updates